Skip to content
★ Sign in to follow
TR

Tissue Regenix Group plc Stock: price and insider trades · United Kingdom

ISIN GB00B5SGVL29GB·

No insider purchase over the last 90 days. The latest, by Brian Phillips, was filed 15 Sept 2023.

Tissue Regenix Group plc: what insiders have been doing

This page follows insider dealings at Tissue Regenix Group plc as filed with RNS (LSE). Nothing new has been filed by managers of Tissue Regenix Group plc in twelve months, the latest record being from 15 September 2023.

Looking back to 2017, when coverage begins, insiders filed 12 purchases and no sales.

Source: insider filings from RNS (LSE). Past trades are no guide to future returns.

Insider Decl.
19
Thresholds
n/a
Buy Volume
€210,829
12 ops. · all time
Sell Volume
n/a
n/a

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

· cache

Last declaration on 15 September 2023
Declarations19 total
  • ▲
    Non-Executive DirectorExecutives
    37 GBP15RNS
    6,773 shares@ £0.0054100.0% of flowLondon Stock Exchange, AIM MarketRNS:4901948
    Canonical exit: 14 Dec 2023 (T+90)
  • ▲
    Chief Executive OfficerExecutives
    9,700 GBP25FCA-NSM
    2,000,000 shares@ £0.004829.4% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4527051
    Canonical exit: 27 Dec 2022 (T+90)
  • ▲
    Non-executive directorExecutives
    14,990 GBP30FCA-NSM
    2,758,000 shares@ £0.0054100.0% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4343296
    Canonical exit: 18 Jul 2022 (T+90)
  • ▲
    Chief Executive OfficerExecutives
    7,854 GBP37FCA-NSM
    1,785,000 shares@ £0.004425.6% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4330505-0
    Canonical exit: 4 Jul 2022 (T+90)
  • ▲
    Chief Financial OfficerExecutives
    7,854 GBP33FCA-NSM
    1,785,000 shares@ £0.004424.3% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4330505-1
    Canonical exit: 4 Jul 2022 (T+90)
  • ▲
    Chief Executive OfficerExecutives
    7,535 GBP30FCA-NSM
    1,408,450 shares@ £0.0054100.0% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4220902
    Canonical exit: 22 Mar 2022 (T+90)
  • ▲
    Non-executive directorExecutives
    54,729 GBP25FCA-NSM
    9,000,000 shares@ £0.006159.1% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4121658
    Canonical exit: 22 Dec 2021 (T+90)
  • ▲
    Chief Financial OfficerExecutives
    7,276 GBP21FCA-NSM
    1,086,000 shares@ £0.006722.0% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4105552
    Canonical exit: 8 Dec 2021 (T+90)
  • ▲
    Non-Executive DirectorExecutives
    17,320 GBP9FCA-NSM
    2,886,671 shares@ £0.00618.7% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4025461
    Canonical exit: 23 Sept 2021 (T+90)
  • ▲
    Non-Executive DirectorExecutives
    20,617 GBP9FCA-NSM
    3,436,085 shares@ £0.00622.3% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:4019450
    Canonical exit: 16 Sept 2021 (T+90)
  • ▲
    Chief Executive OfficerExecutives
    14,274 GBP39FCA-NSM
    2,068,750 shares@ £0.006945.1% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:3969816
    Canonical exit: 8 Aug 2021 (T+90)
  • ▲
    Chief Financial OfficerExecutives
    18,054 GBP24FCA-NSM
    2,821,000 shares@ £0.006453.7% of flowLondon Stock Exchange, AIM MarketISIN GB00B5SGVL29FCA-NSM:3969072
    Canonical exit: 5 Aug 2021 (T+90)
  • ●
    DirectorExecutives
    200,000 GBP19FCA-NSM
    2,000,000 shares@ £0.10100.0% of flowOutside a trading venueFCA-NSM:LSE20170809143001_13324732_20200330131542971_6184-0
  • ●
    DirectorExecutives
    100,000 GBP19FCA-NSM
    1,000,000 shares@ £0.10100.0% of flowOutside a trading venueFCA-NSM:LSE20170809143001_13324732_20200330131542971_6184-1
  • ●
    DirectorExecutives
    15,000 GBP19FCA-NSM
    150,000 shares@ £0.10100.0% of flowOutside a trading venueFCA-NSM:LSE20170809143001_13324732_20200330131542971_6184-2
  • ●
    DirectorExecutives
    60,000 GBP19FCA-NSM
    600,000 shares@ £0.10100.0% of flowOutside a trading venueFCA-NSM:LSE20170809143001_13324732_20200330131542971_6184-3
  • ●
    DirectorExecutives
    30,000 GBP19FCA-NSM
    300,000 shares@ £0.10100.0% of flowOutside a trading venueFCA-NSM:LSE20170809143001_13324732_20200330131542971_6184-4
  • ●
    DirectorExecutives
    30,000 GBP19FCA-NSM
    300,000 shares@ £0.10100.0% of flowOutside a trading venueFCA-NSM:LSE20170809143001_13324732_20200330131542971_6184-5
  • ●
    DirectorExecutives
    25,000 GBP19FCA-NSM
    250,000 shares@ £0.10100.0% of flowOutside a trading venueFCA-NSM:LSE20170809143001_13324732_20200330131542971_6184-6

19 of 19 declarations

About Tissue Regenix Group plc

Tissue Regenix Group plc is a company focused on tissue regeneration, providing innovative solutions for regenerative medicine. It is listed on the London Stock Exchange under the ticker XLON.